These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

216 related items for PubMed ID: 2510742

  • 1. General pharmacology of beraprost sodium. 1st communication: effect on the central nervous system.
    Murata T, Sakaya S, Hoshino T, Umetsu T, Hirano T, Nishio S.
    Arzneimittelforschung; 1989 Aug; 39(8):860-6. PubMed ID: 2510742
    [Abstract] [Full Text] [Related]

  • 2. General pharmacology of beraprost sodium. 2nd communication: effect on the autonomic, cardiovascular and gastrointestinal systems, and other effects.
    Murata T, Murai T, Kanai T, Ogaki Y, Sanai K, Kanda H, Sato S, Kajikawa N, Umetsu T, Matsuura H.
    Arzneimittelforschung; 1989 Aug; 39(8):867-76. PubMed ID: 2510743
    [Abstract] [Full Text] [Related]

  • 3. Effect of beraprost sodium on peripheral circulatory disturbances induced by various stimuli.
    Nishio S, Yamada N, Endoh T, Isogaya M, Fukatsu Y, Nishimura S, Kanai N, Umetsu T.
    Arzneimittelforschung; 1989 Oct; 39(10):1229-34. PubMed ID: 2514691
    [Abstract] [Full Text] [Related]

  • 4. Studies on the antiplatelet effect of the stable epoprostenol analogue beraprost sodium and its mechanism of action in rats.
    Umetsu T, Murata T, Nishio S.
    Arzneimittelforschung; 1989 Jan; 39(1):68-73. PubMed ID: 2541730
    [Abstract] [Full Text] [Related]

  • 5. Effect of beraprost sodium on peripheral circulation insufficiency in rats and rabbits.
    Murai T, Muraoka K, Saga K, Sakai A, Sato N, Amemiya K, Yajima M, Murata T, Umetsu T, Nishio S.
    Arzneimittelforschung; 1989 Aug; 39(8):856-9. PubMed ID: 2510741
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. General pharmacological profile of the novel muscarinic receptor agonist SNI-2011, a drug for xerostomia in Sjögren's syndrome. 1st communication: effects on general behavior and central nervous system.
    Arisawa H, Imai E, Fujise N, Fukui K, Masunaga H.
    Arzneimittelforschung; 2002 Aug; 52(1):14-20. PubMed ID: 11838269
    [Abstract] [Full Text] [Related]

  • 9. General pharmacological properties of the new vasodilator flosequinan.
    Ikezono K, Fujita S, Umezato M, Hosoki E, Toba Y, Kusunoki A, Shintani S.
    Arzneimittelforschung; 1992 Oct; 42(10):1200-11. PubMed ID: 1472141
    [Abstract] [Full Text] [Related]

  • 10. General pharmacology of recombinant human tumor necrosis factor. 2nd communication: effects on central nervous system functions.
    Kurumiya S, Miura Y, Nakatsuji K, Dodo M, Hori M, Ito T.
    Arzneimittelforschung; 1990 Feb; 40(2 Pt 1):225-31. PubMed ID: 2334465
    [Abstract] [Full Text] [Related]

  • 11. General pharmacological properties of the main metabolite of flosequinan.
    Fujita S, Ikezono K, Umezato M, Hosoki E, Toba Y, Ishikawa M, Kusunoki A, Shintani S.
    Arzneimittelforschung; 1992 Oct; 42(10):1212-22. PubMed ID: 1335257
    [Abstract] [Full Text] [Related]

  • 12. [Effects of suloctidil on the central and peripheral nervous systems].
    Nishi H, Watanabe T, Mori M.
    Nihon Yakurigaku Zasshi; 1983 Sep; 82(3):191-212. PubMed ID: 6319248
    [Abstract] [Full Text] [Related]

  • 13. General pharmacological properties of the human corticotropin-releasing hormone corticorelin (human).
    Andoh K, Kimura T, Saeki I, Tabata R, Yamazaki S, Eguchi I, Hanazuka M, Horii D, Munt PL, Davis AS.
    Arzneimittelforschung; 1994 Jun; 44(6):715-26. PubMed ID: 8053970
    [Abstract] [Full Text] [Related]

  • 14. General pharmacology of the new antimuscarinic compound vamicamide.
    Yamamoto T, Honbo T, Tokoro K, Kojimoto Y, Kodama R, Ohtsuka M, Shimomura K.
    Arzneimittelforschung; 1995 Dec; 45(12):1274-84. PubMed ID: 8595084
    [Abstract] [Full Text] [Related]

  • 15. Specific binding of the new stable epoprostenol analogue beraprost sodium to prostacyclin receptors on human and rat platelets.
    Kajikawa N, Nogimori K, Murata T, Nishio S, Uchiyama S.
    Arzneimittelforschung; 1989 Apr; 39(4):495-9. PubMed ID: 2665758
    [Abstract] [Full Text] [Related]

  • 16. Pharmacological studies with the alpha 2-adrenoceptor antagonist midaglizole. Part II: Central and peripheral nervous systems.
    Hirohashi M, Takasuna K, Kasai Y, Usui C, Kojima H.
    Arzneimittelforschung; 1991 Jan; 41(1):19-24. PubMed ID: 1675569
    [Abstract] [Full Text] [Related]

  • 17. General pharmacology of recombinant human basic fibroblast growth factor.
    Okumura M, Yajima M, Nishimura T, Ikeda H, Nishimori T.
    Arzneimittelforschung; 1996 Jul; 46(7):727-39. PubMed ID: 8842346
    [Abstract] [Full Text] [Related]

  • 18. The effects of beraprost Na, a stable prostacyclin analog, on animal models of stroke.
    Hirano T, Yamori Y, Kanai N, Umetsu T, Nishio S.
    Mol Chem Neuropathol; 1992 Aug; 17(1):91-102. PubMed ID: 1388452
    [Abstract] [Full Text] [Related]

  • 19. Pharmacological studies of mabuterol, a new selective beta 2-stimulant. III: Effects on the central nervous system, striated muscle and carbohydrate and lipid metabolism.
    Osada E, Sakaya S, Sanai K, Seri K.
    Arzneimittelforschung; 1984 Aug; 34(11A):1652-8. PubMed ID: 6152158
    [Abstract] [Full Text] [Related]

  • 20. General pharmacology of the novel angiotensin converting enzyme inhibitor alacepril. 2nd communication: Effects on central nervous and sensory systems and on the other functions.
    Matsuno Y, Hori H, Oka M, Nakamura H, Ito T, Kadokawa T.
    Arzneimittelforschung; 1986 Aug; 36(1):62-8. PubMed ID: 3513778
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.